Atorvastatin and Tofacitinib (Combination)

The combination of atorvastatin and tofacitinib represents a therapeutic approach used in rheumatoid arthritis (RA) patients to address both the inflammatory disease process and the lipid abnormalities associated with tofacitinib treatment. Tofacitinib is an oral Janus kinase (JAK) inhibitor approved for treating moderately to severely active RA. One of its notable side effects is elevation of cholesterol levels, including total cholesterol, LDL-cholesterol, and triglycerides[1][4]. Atorvastatin, a statin medication, has been shown to effectively reduce these tofacitinib-associated lipid elevations. ## Clinical Evidence A randomized, placebo-controlled phase 2 study specifically evaluated the efficacy of atorvastatin in modifying lipids in RA patients receiving tofacitinib. In this study, patients received tofacitinib 10 mg twice daily for 12 weeks, and at week 6, they were randomized to receive either atorvastatin 10 mg once daily or placebo[1]. The results demonstrated that atorvastatin significantly reduced tofacitinib-associated increases in: - Total cholesterol - LDL-cholesterol - Triglycerides - Apolipoprotein B The primary endpoint showed a 35.3% reduction in LDL-cholesterol with atorvastatin versus a 5.8% increase with placebo from week 6 to week 12[1]. ## Cardiovascular Risk Implications More recent data from the ORAL Surveillance study suggests that statin use may mitigate the increased cardiovascular risk associated with JAK inhibitors like tofacitinib. Among patients with a history of atherosclerotic cardiovascular disease (ASCVD) taking tofacitinib, those using statins had lower rates of major adverse cardiovascular events (MACE) compared to those not using statins[4][6]. In patients with ASCVD history who were not using statins, the occurrence of MACE was higher with tofacitinib versus TNF inhibitors. However, in those with ASCVD history who were using statins, there did not appear to be a significant difference in MACE incidence between tofacitinib and TNF inhibitors[6]. ## Drug Interactions According to available information, no specific drug interactions have been identified between atorvastatin and tofacitinib (Xeljanz)[2]. However, this doesn't necessarily mean no interactions exist, and appropriate monitoring would still be recommended when using these medications together. The combination of atorvastatin and tofacitinib represents an important therapeutic strategy for managing both the inflammatory disease process in RA and the lipid abnormalities that can occur with tofacitinib treatment, potentially reducing associated cardiovascular risks.

Other names

CP-690550 + atorvastatintasocitinib + atorvastatin